LAG-3 along with PD-1 dual blockade have been shown in mouse models to improve anti-tumor immune response by increasing CD8+ tumor-infiltrating cells in the tumor microenvironment and decreasing T regulatory cells [49]. The gene discussed is CD8A; the disease is neoplasm.